News
Median Technologies to host a live webcast and provide a company update on July 12, 2022
Regulatory News:
Median Technologies (ALMDT:PA) announced today that Fredrik Brag, CEO and founder of Median Technologies, will provide a company update on July 12, 2022 at 11:00 am CEST during a
Bryan Garnier & Co Initiates the Coverage of Median Technologies with a “Buy” Recommendation
Regulatory News:
Median Technologies (ALMDT) announces today the publication of an initiation report by Bryan Garnier & Co, a pan-European investment bank focusing on growth companies.
In the
Median Technologies to Present an Abstract at the 2022 ASCO Annual Meeting, June 3 – 7, 2022, McCormick Place, Chicago, IL, USA
Regulatory News:
Median Technologies (ALMDT) announced today that it will be presenting an abstract at the 2022 ASCO Annual Meeting, June 3-7, McCormick Place, Chicago, IL, USA (exhibition dates
Median Technologies Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials
Regulatory News:
Median Technologies (Paris:ALMDT) announces that the company is expanding its portfolio of services with Imaging Lab, a new entity whose mission is to leverage AI, data mining
Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 14, 2022
Regulatory News:
The shareholders of Median Technologies (ALMDT:PA) are invited to participate at the Shareholders’ Ordinary and Extraordinary General Meeting which will be held on Tuesday June
BILENDI: Q1 2022 revenues: €13.4 million, up +52% (+13.7% on a pro forma basis)
Median Technologies Is Moving Forward With the FDA Interactions for Its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device
Regulatory News:
Median Technologies (ALMDT) announces today that the company has received feedback from the United States Food and Drug Administration (FDA) regarding the 513(g) submission done
Median Technologies Reports Full-Year 2021 Results and Business Indicators for the First Quarter of 2022
Regulatory News:
Median Technologies (Euronext Growth - ALMDT) (Paris:ALMDT) whose Board of Directors met on April 20, 2022 to close the consolidated financial statements for the year ending
Median Technologies Brings Forward Its 2021 Annual Results Publication to April 21, 2022
Regulatory News:
Median Technologies (ALMDT:PA) (Paris:ALMDT) announces today that the company will publish its 2021 annual results on April 21, 2022 after trading. The 2021 annual results
Median Technologies Announces Design Completion of its iBiopsy® Lung Cancer Screening End-to-end CADe/CADx Software as Medical Device (SaMD) with Outstanding Sensitivity & Specificity Performance
Regulatory News:
Median Technologies (ALMDT:PA) announces outstanding performance of its iBiopsy LCS AI/ML tech-based end-to-end CADe/CADx Software as Medical Device, intended to enable early
Median Technologies Files FDA 513(g) Regulatory Submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device
Regulatory News:
Median Technologies (ALMDT) announces today that the company has filed a 513(g) submission on Feb. 17, 2022 to the United States Food and Drug Administration (FDA) for its
Median Technologies to Participate in the Cowen’s 42nd Annual Health Care Conference
Regulatory News:
Median Technologies (Paris: ALMDT), will be participating in the Cowen’s 42nd Annual Health Care Conference, taking place virtually on March 7-9, 2022.
Fredrik Brag, Median’s
Median Technologies Announces 2021 Revenue of €20.5 Million, Up 52%, and a Strengthened Cash Position of €39 Million
Regulatory News:
Median Technologies (ALMDT:PA) today announces its business activity indicators for the full year 2021. In 2021, the company’s business continued to grow at a rapid pace.
Median Technologies Announces Outstanding Lung Nodule Detection (CADe1) Performance for iBiopsy® Lung Cancer Screening
Regulatory News:
Median Technologies (ALMDT:PA) announces outstanding performance for its iBiopsy® Lung Cancer Screening (LCS) CADe algorithm in detecting potentially cancerous lung nodules.
Median Technologies: Financial Communications Schedule for the First Half of 2022
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT:PA), announces the publication date for its 2021 results:
Publication
Date
2021 results
April 26, 2022*
BILENDI: Bilendi surpasses 2023 revenue target 2 years ahead of schedule and changes dimension
BILENDI: Bilendi announces the completion of the the acquisition of the respondi group
BILENDI: Bilendi acquires the respondi Group, a European player in data collection for market research